{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:05:17Z","timestamp":1777896317288,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Lower Saxony Ministry of Culture and Sciences","award":["25A.5-7251-99-3\/00"],"award-info":[{"award-number":["25A.5-7251-99-3\/00"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.vph.2018.06.012","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T20:37:53Z","timestamp":1529440673000},"page":"69-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Treatment of cyclosporine induced hypertension: Results from a long-term observational study using different antihypertensive medications"],"prefix":"10.1016","volume":"115","author":[{"given":"Kim","family":"Marienhagen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Lehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Klempnauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Hecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Borlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2018.06.012_bb0005","first-page":"230386","article-title":"Cyclosporine: a review","volume":"2012","author":"Tedesco","year":"2012","journal-title":"J. Transp. Secur."},{"key":"10.1016\/j.vph.2018.06.012_bb0010","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.vph.2018.06.012_bb0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000345988","article-title":"Mechanisms of cyclosporine-induced renal cell apoptosis: a systematic review","volume":"37","author":"Xiao","year":"2013","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.vph.2018.06.012_bb0020","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1210\/jc.2011-0657","article-title":"Approach to the patient with new-onset diabetes after transplant (NODAT)","volume":"96","author":"Lane","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.vph.2018.06.012_bb0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2377-10-30","article-title":"Vasospasm is a significant factor in cyclosporine-induced neurotoxicity: case report","volume":"10","author":"Braakman","year":"2010","journal-title":"BMC Neurol."},{"key":"10.1016\/j.vph.2018.06.012_bb0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00228-012-1355-x","article-title":"ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients","volume":"69","author":"Garcia","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.vph.2018.06.012_bb0035","series-title":"Arzneiverordnungs-Report 2013","first-page":"667","article-title":"Immuntherapeutika und zytostatika","author":"Zeller","year":"2013"},{"key":"10.1016\/j.vph.2018.06.012_bb0040","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1399-0012.2005.00357.x","article-title":"Endothelin-1 plasma levels and hypertension in cyclosporine-treated renal transplant patients","volume":"19","author":"Cauduro","year":"2005","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.vph.2018.06.012_bb0045","doi-asserted-by":"crossref","DOI":"10.5402\/2013\/165937","article-title":"Hypertension: the neglected complication of transplantation","volume":"2013","author":"Aparicio","year":"2013","journal-title":"ISRN Hypertens."},{"key":"10.1016\/j.vph.2018.06.012_bb0050","first-page":"171","article-title":"Arterial hypertension in renal transplant recipients","volume":"61","author":"Basic-Jukic","year":"2007","journal-title":"Acta Med. Croatica"},{"key":"10.1016\/j.vph.2018.06.012_bb0055","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.transproceed.2007.03.057","article-title":"Effect of hypertension on transplant kidney function: three year of follow-up","volume":"39","author":"Raiss Jalali","year":"2007","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.vph.2018.06.012_bb0060","series-title":"PASS. 2017","author":"Hintze","year":"2017"},{"key":"10.1016\/j.vph.2018.06.012_bb0065","first-page":"865","article-title":"Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance","volume":"23","author":"Liu","year":"2007","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.vph.2018.06.012_bb0070","volume":"2017","author":"Whelton","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2018.06.012_bb0075","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1432-2277.2009.00922.x","article-title":"Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients","volume":"22","author":"Hillebrand","year":"2009","journal-title":"Transpl. Int."},{"key":"10.1016\/j.vph.2018.06.012_bb0080","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1097\/HJH.0b013e32834bd1e7","article-title":"Pathogenesis and management of hypertension after kidney transplantation","volume":"29","author":"Chatzikyrkou","year":"2011","journal-title":"J. Hypertens."},{"key":"10.1016\/j.vph.2018.06.012_bb0085","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1432-2277.2011.01242.x","article-title":"Hypertension in kidney transplant recipients","volume":"24","author":"Ponticelli","year":"2011","journal-title":"Transpl. Int."},{"key":"10.1016\/j.vph.2018.06.012_bb0090","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/TP.0b013e318169c29e","article-title":"Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression","volume":"85","author":"Mikhalski","year":"2008","journal-title":"Transplantation"},{"issue":"Suppl 4:iv","key":"10.1016\/j.vph.2018.06.012_bb0095","first-page":"39","article-title":"Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study","volume":"27","author":"Morales","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.vph.2018.06.012_bb0100","article-title":"Antihypertensive treatment for kidney transplant recipients","author":"Cross","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.vph.2018.06.012_bb0105","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/hc4101.096153","article-title":"Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the council on the kidney in cardiovascular disease and the council for high blood pressure research of the American heart association","volume":"104","author":"Schoolwerth","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2018.06.012_bb0110","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Investigators","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2018.06.012_bb0115","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1161\/01.HYP.33.3.862","article-title":"ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients","volume":"33","author":"Hausberg","year":"1999","journal-title":"Hypertension"},{"issue":"Suppl. 1","key":"10.1016\/j.vph.2018.06.012_bb0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00003495-200868001-00005","article-title":"Mechanisms and management of proteinuria in kidney transplant patients","volume":"68","author":"Barama","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.vph.2018.06.012_bb0125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1399-0012.2004.00315.x","article-title":"Hypertension, antihypertensive agents and outcomes following renal transplantation","volume":"19","author":"Tutone","year":"2005","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.vph.2018.06.012_bb0130","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1681\/ASN.2006050543","article-title":"No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report","volume":"17","author":"Opelz","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.vph.2018.06.012_bb0135","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.2174\/1381612811319170009","article-title":"Angiotensin II blockade and renal protection","volume":"19","author":"Kobori","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.vph.2018.06.012_bb0140","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jchf.2014.05.014","article-title":"The effects of dose reduction of furosemide on glomerular filtration rate in stable systolic heart failure","volume":"2","author":"Mckie","year":"2014","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.vph.2018.06.012_bb0145","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ahj.2010.05.032","article-title":"Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization","volume":"160","author":"Abdel-Qadir","year":"2010","journal-title":"Am. Heart J."},{"key":"10.1016\/j.vph.2018.06.012_bb0150","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5301\/jn.5000174","article-title":"Pathogenesis of calcineurin inhibitor-induced hypertension","volume":"25","author":"Hoorn","year":"2012","journal-title":"J. Nephrol."},{"key":"10.1016\/j.vph.2018.06.012_bb0155","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1038\/sj.ki.5001835","article-title":"Beta blockers in the management of chronic kidney disease","volume":"70","author":"Bakris","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.vph.2018.06.012_bb0160","doi-asserted-by":"crossref","first-page":"919256","DOI":"10.1155\/2014\/919256","article-title":"Beta-blockers in the Management of Hypertension and\/or chronic kidney disease","volume":"2014","author":"Tomiyama","year":"2014","journal-title":"Int. J. Hypertens."},{"key":"10.1016\/j.vph.2018.06.012_bb0165","article-title":"Beta-blockers for hypertension","volume":"1","author":"Wiysonge","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.vph.2018.06.012_bb0170","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/08037059509077575","article-title":"ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension","volume":"4","author":"Himmelmann","year":"1995","journal-title":"Blood Press."},{"key":"10.1016\/j.vph.2018.06.012_bb0175","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00210-014-1074-1","article-title":"Central modulation of cyclosporine-induced hypertension","volume":"388","author":"El-Gowelli","year":"2015","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.vph.2018.06.012_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016319","article-title":"HNF4alpha dysfunction as a molecular rational for cyclosporine induced hypertension","volume":"6","author":"Niehof","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vph.2018.06.012_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004662","article-title":"HNF4alpha and HNF1alpha dysfunction as a molecular rational for cyclosporine induced posttransplantation diabetes mellitus","volume":"4","author":"Borlak","year":"2009","journal-title":"PLoS ONE"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189117303622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189117303622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:18:07Z","timestamp":1761527887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189117303622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":37,"alternative-id":["S1537189117303622"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2018.06.012","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of cyclosporine induced hypertension: Results from a long-term observational study using different antihypertensive medications","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2018.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}